Discontinued — last reported Q4 '25
Zoetis Impairment Charges decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $2.00M to $0.00. Over 4 years (FY 2021 to FY 2025), Impairment Charges shows relatively stable performance with a 0.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
High impairment charges suggest poor capital allocation or a decline in the competitive value of the company's assets.
Impairment charges are non-cash write-downs taken when the carrying value of an asset exceeds its fair market value. Thi...
Common in industries with high intangible asset bases, such as pharma and consumer goods.
impairment_charges_cf| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $13.00M | $5.00M | $28.00M | $1.00M | $1.00M | $5.00M | $46.00M | $1.00M | $12.00M | $14.00M | $19.00M | $2.00M | $11.00M | $3.00M | $15.00M | $2.00M | $31.00M | $6.00M | $8.00M | $0.00 |
| QoQ Change | — | -61.5% | +460.0% | -96.4% | +0.0% | +400.0% | +820.0% | -97.8% | >999% | +16.7% | +35.7% | -89.5% | +450.0% | -72.7% | +400.0% | -86.7% | >999% | -80.6% | +33.3% | -100.0% |
| YoY Change | — | — | — | — | -92.3% | +0.0% | +64.3% | +0.0% | >999% | +180.0% | -58.7% | +100.0% | -8.3% | -78.6% | -21.1% | +0.0% | +181.8% | +100.0% | -46.7% | -100.0% |